查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877391

抗癌药物市场：依给药途径、药物类别、适应症、通路、剂型、最终用户、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Anticancer Drug Market, By Route of Administration, By Drug Class, By Indication, By Distribution Channels, By Dosage Form, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 398 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年抗癌药物市场规模价值 1,666.6956 亿美元，从 2025 年到 2032 年将以 9.5% 的复合年增长率成长。

抗癌药物，也称为抗肿瘤药物，是指能够阻止恶性或癌细胞生长和扩散的药物。全球癌症发生率的上升以及肿瘤学研究投入的增加是推动市场成长的主要因素，这将促进标靶疗法和个人化医疗的发展。然而，抗癌治疗的高昂费用和严格的监管审批流程限制了中低收入国家获得这些药物的机会。儘管如此，免疫疗法和精准肿瘤学的发展仍蕴藏着巨大的机会，它们利用基因谱分析提供更有效、更毒性的治疗方案。生物製剂和联合疗法的持续创新预计将在未来几年推动市场成长。

抗癌药物市场－市场动态

癌症发生率上升将促进市场成长

全球癌症发生率的上升是抗癌药物市场成长的主要驱动力之一。人口老化、生活方式的改变、环境污染以及遗传易感性等因素都导致了全球癌症病例的增加。随着患者数量的增长，对标靶治疗、免疫疗法和个人化药物等有效且先进的治疗方案的需求也随之增长。这种需求的激增促使製药公司加大研发投入，开发新型疗法以改善病患的治疗效果。例如，世界卫生组织（WHO）预测，到2040年，全球新增癌症病例将从2018年的1810万例增至2,940万例，凸显了对创新抗癌药物的迫切需求，并支撑了预测期内市场的持续成长。

抗癌药物市场細項分析：

全球抗癌药物市场按给药途径、药物类别、适应症、分销管道、剂型、最终用户和地区进行细分。

从剂型来看，抗癌药物市场可分为固体製剂（片剂、胶囊）、注射剂（预充填式註射器等）、液体製剂及其他剂型。其中，注射剂市场是重要的收入来源，这主要得益于生物製剂和标靶疗法的日益普及，这些疗法需要透过肠外途径给药以提高疗效和控制药物释放。在肿瘤治疗领域，注射剂应用广泛，因为它们能够实现精准给药、快速全身吸收，并在医疗监督下使用时改善治疗效果。此外，生物相似药和注射剂仿製药的日益普及正在扩大药物的可及性并推动市场扩张。例如，2020年9月，迈兰公司宣布在美国推出氟维司群注射液（250毫克/5毫升），这是阿斯特捷利康公司用于治疗某些类型晚期乳癌的氟维司群注射液的仿製药，这表明该领域持续的创新和市场活跃度。

根据药物类别，标靶治疗是抗癌药物市场的重要组成部分，因为它能够选择性地攻击恶性细胞，同时最大限度地减少对健康组织的损伤，从而提高治疗效果并降低毒性。这种精准的治疗方法直接针对疾病机制，同时最大限度地减少脱靶效应，因此比传统化疗更容易被接受。不断增长的FDA批准的单株抗体、激酶抑制剂和免疫调节剂产品组合表明癌症研究和开发取得了显着进展。此外，基因组检测和伴随诊断的结合提高了治疗的准确性，从而实现了更个人化和有效的癌症治疗。越来越多的新型标靶疗法获得监管部门批准，加上强大的在研药物管线，正在推动该领域的市场潜力。例如，2023年6月，美国FDA批准了达拉非尼和曲美替尼联合用药用于治疗BRAF V600E突变型癌症的儿童和成人患者，这凸显了持续的创新和临床进展正在推动标靶治疗领域的成长。

抗癌药物市场—地域性洞察

抗癌药物市场呈现出显着的区域差异，这主要受医疗基础设施、癌症发生率以及获得先进疗法的机会等因素的影响。亚太地区仍是该市场的主要成长区域，约占全球市场份额的20%。癌症发生率的上升、医疗支出的增加以及现代肿瘤治疗手段的普及，都推动了该地区市场的成长。快速的城市化、生活方式的改变以及人口老化也加剧了癌症发生率的上升。中国、印度和日本等国家正大力投资肿瘤研究、临床试验和医疗基础设施建设，以满足日益增长的癌症治疗需求。此外，病患意识的提升、政府的支持性措施以及完善的医保报销机制，也促进了标靶药物、免疫疗法和联合疗法等新型疗法的应用。

中国抗癌药物市场—国家概况

中国庞大的人口基数、不断上升的癌症发生率以及不断完善的医疗基础设施，使其成为亚太地区抗癌药物市场的重要驱动力。世界卫生组织的资料显示，预计2025年，中国将新增约430万例癌症病例，其中以肺癌、乳癌和大肠癌最为常见。中国政府正大力投资肿瘤学研究、临床试验和医院网路建设。公众意识的提高、标靶治疗和免疫疗法等创新疗法的普及以及有利的医保政策，正在加速先进抗癌药物的推广应用，使中国成为该地区占据主导地位且快速增长的市场。

抗癌药物市场－竞争格局：

罗氏控股、诺华、百时美施贵宝、辉瑞、默克、阿斯特捷利康和强生是抗癌药物市场的主要参与者。这些公司凭藉着标靶治疗、免疫肿瘤学和精准医疗领域的进步，不断加剧市场竞争。免疫检查点抑制剂、CAR-T细胞疗法和抗体药物偶联物（ADC）的日益普及正在改变治疗模式，并推动研发投入。为了加强肿瘤产品线并拓展全球业务，各公司之间进行策略合作、併购活动十分普遍。此外，人工智慧驱动的药物发现平台与基于生物标记的患者筛选相结合，正在加速创新。为了应对日益严重的全球癌症负担，竞争格局呈现出快速的技术革新、临床试验规模的扩大以及对个性化、高性价比癌症疗法的关注等特点。

目录

第一章：抗癌药物市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 抗癌药物市场概况（依给药途径划分）
    • 抗癌药物市场概况（按药物类别划分）
    • 抗癌药物市场概况（依适应症划分）
    • 抗癌药物市场按分销管道分類的概况
    • 抗癌药物市场按剂型分類的概况
    • 抗癌药物市场概况（依终端使用者划分）
    • 各国抗癌药物市场概况
    • 抗癌药物市场概况（按地区划分）
  • 竞争洞察

第三章：抗癌药物市场主要趋势

  • 抗癌药物市场驱动因素
    • 市场驱动因素的影响分析
  • 抗癌药物市场限制因素
    • 市场限制因素的影响分析
  • 抗癌药物市场机会
  • 抗癌药物市场未来趋势

第四章：抗癌药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：抗癌药物市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：抗癌药物市场概况

  • 2024年抗癌药物市场占有率分析
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：抗癌药物市场－依给药途径划分

  • 概述
    • 按给药途径分類的细分市占率分析
    • 静脉注射（IV）
    • 皮下
    • 口服
    • 局部/局部

第八章：抗癌药物市场－依药物类别划分

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 化疗
    • 免疫疗法（检查点抑制剂、CAR-T疗法、TCR疗法）
    • 单株抗体/生物製剂
    • 荷尔蒙疗法
    • 标靶治疗
    • 其他（溶瘤病毒、联合疗法、辅助疗法）

第九章：抗癌药物市场－依适应症划分

  • 概述
    • 按指标分類的细分市场占有率分析
    • 乳癌
    • 肺癌
    • 摄护腺癌
    • 胃肠道癌症
    • 血癌
    • 妇科癌症
    • 其他的

第十章：抗癌药物市场－依分销管道划分

  • 概述
    • 按分销管道分類的细分市场份额分析
    • 网路药房
    • 医院药房
    • 零售药房

第十一章：抗癌药物市场－以剂型划分

  • 概述
    • 按剂型分類的细分市场份额分析
    • 固体（片剂、胶囊）
    • 注射剂（预充式註射器、其他）
    • 液体
    • 其他的

第十二章：抗癌药物市场－以终端使用者划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 专科诊所
    • 医院
    • 居家照护
    • 其他的

第十三章：抗癌药物市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美抗癌药物主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（依给药途径划分）
    • 北美市场规模及预测（按药物类别划分）
    • 北美市场规模及预测（依适应症划分）
    • 北美市场规模及预测（按分销管道划分）
    • 北美市场规模及预测（以剂型划分）
    • 北美市场规模及预测（依最终用户划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲抗癌药物主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（依给药途径划分）
    • 欧洲市场规模及预测（按药物类别划分）
    • 欧洲市场规模及预测（依适应症划分）
    • 欧洲市场规模及预测（依分销通路划分）
    • 欧洲市场规模及预测（以剂型划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区抗癌药物主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依给药途径划分）
    • 亚太地区市场规模及预测（依药物类别划分）
    • 亚太地区市场规模及预测（依适应症划分）
    • 亚太地区市场规模及预测（依分销管道划分）
    • 亚太地区市场规模及预测（依剂型划分）
    • 亚太市场规模及预测（依最终用户划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗癌药物主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（依给药途径划分）
    • 拉丁美洲市场规模及预测（按药物类别划分）
    • 拉丁美洲市场规模及预测（依适应症划分）
    • 拉丁美洲市场规模及预测（按分销管道划分）
    • 拉丁美洲市场规模及预测（以剂型划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲抗癌药物主要生产商
    • 中东和非洲市场规模及预测（按国家/地区划分）
    • 中东和非洲市场规模及预测（按给药途径划分）
    • 中东和非洲市场规模及预测（按药物类别划分）
    • 中东和非洲市场规模及预测（按适应症划分）
    • 中东和非洲市场规模及预测（按分销管道划分）
    • 中东和非洲市场规模及预测（按剂型划分）
    • 中东和非洲市场规模及预测（按最终用户划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十四章：主要供应商分析－抗癌药物产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Novartis
    • Pfizer
    • Merck & Co. (MSD)
    • Bristol Myers Squibb (BMS)
    • AstraZeneca
    • Roche/Genentech
    • Johnson & Johnson/Janssen
    • Sanofi
    • Eli Lilly & Co.
    • Takeda
    • Amgen
    • BeiGene
    • Regeneron
    • Bluebird Bio
    • Seagen
    • Moderna
    • Genmab
    • Incyte
    • Exelixis
    • Hutchmed / Chi-Med
    • Others

第十五章：360度分析师视角

第十六章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5765

Anticancer Drug Market size was valued at US$ 166,669.56 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.

Anticancer drugs, also known as antineoplastic drugs, are medications that prevent malignant or cancerous cells from growing and spreading. The market is primarily driven by rising global cancer prevalence and increased investments in oncology research, which will result in the development of targeted therapies and personalized medicine. However, the high cost of anticancer treatments and stringent regulatory approval processes limit access in low- and middle-income countries. Nevertheless, significant opportunities exist for the advancement of immunotherapies and precision oncology, which use genetic profiling to provide more effective and less toxic treatment options. Continuous innovation in biologics and combination therapies is expected to drive market growth in the coming years.

Anticancer Drug Market- Market Dynamics

Increasing Prevalence of Cancer to Augment Market Growth

The rising global cancer incidence is one of the primary drivers of the anticancer drug market's growth. Aging populations, changing lifestyles, environmental pollution, and genetic predispositions all contribute to an increase in cancer cases around the world. As the number of patients grows, so does the demand for effective and advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines. This surge is encouraging pharmaceutical companies to increase their R&D investments and develop novel therapeutics to improve patient outcomes. For instance, the World Health Organization (WHO) predicts that the number of new cancer cases will rise from 18.1 million in 2018 to 29.4 million by 2040, highlighting the critical need for innovative anticancer drugs and supporting continued market growth during the forecast period.

Anticancer Drug Market- Segmentation Analysis:

The Global Anticancer Drug Market is segmented on the basis of Route of Administration, Drug Class, Indication, Distribution Channels, Dosage Form, End-Users, and Region.

In terms of Dosage Form, the Anticancer Drug Market is divided into Solid (Tablets, Capsules), Injectable (Prefilled Syringes, Others), Liquid, and Others. Among these, the injectable segment is a significant revenue generator, driven by the growing use of biologics and targeted therapies that require parenteral administration for improved efficacy and controlled release. In oncology, injectables are widely used because they allow for precise dosing, rapid systemic absorption, and improved treatment outcomes when administered under medical supervision. Moreover, the increasing availability of biosimilars and generic injectable formulations is broadening access and driving market expansion. For example, in September 2020, Mylan N.V. announced the U.S. launch of Fulvestrant Injection (250 mg/5 mL), a generic version of AstraZeneca's Faslodex used to treat certain types of advanced breast cancer in women, demonstrating ongoing innovation and market activity in this segment.

Based on drug class, targeted therapy is an important segment of the anticancer drug market due to its ability to selectively attack malignant cells while minimizing damage to healthy tissues, thereby improving treatment efficacy and lowering toxicity. This precision-based approach focuses directly on disease mechanisms while minimizing off-target effects, resulting in higher adoption than conventional chemotherapy. The growing portfolio of FDA-approved monoclonal antibodies, kinase inhibitors, and immune-modulating agents demonstrates significant progress in cancer research and development. Furthermore, the combination of genomic testing and companion diagnostics has increased treatment accuracy, allowing for more personalized and effective cancer care. The growing number of regulatory approvals for novel targeted therapies, combined with a strong pipeline of investigational drugs, is boosting this segment's market potential. For instance, in June 2023, the US FDA approved the combination of dabrafenib and trametinib for pediatric and adult patients with BRAF V600E-mutated cancers, highlighting the ongoing innovation and clinical progress that is driving growth in the targeted therapy segment.

Anticancer Drug Market- Geographical Insights

The Anticancer Drug Market exhibits notable regional diversity, shaped by differences in healthcare infrastructure, cancer prevalence, and access to advanced therapies. Asia-Pacific remains a key growth region for the market, accounting for roughly 20% of the global share. The rising incidence of cancer, increased healthcare expenditure, and expanded access to modern oncology treatments all contribute to growth in this region. Rapid urbanization, lifestyle changes, and an ageing population all contribute to the rise in disease prevalence. Countries such as China, India, and Japan are investing heavily in oncology research, clinical trials, and healthcare infrastructure to meet the rising demand for cancer care. Furthermore, increased patient awareness, supportive government initiatives, and improved reimbursement frameworks are easing the adoption of novel therapies such as targeted drugs, immunotherapies, and combination treatments.

China Anticancer Drug Market- Country Insights

China's large population, rising cancer prevalence, and expanding healthcare infrastructure make it a key driver of the Asia-Pacific anticancer drugs market. According to World Health Organization data, China is expected to see approximately 4.3 million new cancer cases in 2025, with lung, breast, and colorectal cancers being the most common. The government is making substantial investments in oncology research, clinical trials, and hospital networks. Increased awareness, access to innovative therapies such as targeted treatments and immunotherapies, and supportive reimbursement policies are hastening the adoption of advanced anti-cancer drugs, establishing China as a dominant and rapidly growing market in the region.

Anticancer Drug Market- Competitive Landscape:

Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, and Johnson & Johnson are among the anticancer drug market key players. These companies are fueling competition with advances in targeted therapies, immuno-oncology, and precision medicine. The increasing use of checkpoint inhibitors, CAR-T cell therapies, and antibody-drug conjugates (ADCs) is changing treatment paradigms and driving R&D investments. Strategic collaborations, mergers, and acquisitions are common as companies seek to strengthen their oncology pipelines and expand globally. In addition, the combination of AI-powered drug discovery platforms and biomarker-based patient selection is hastening innovation. To address the increasing global cancer burden, the competitive landscape is characterized by rapid technological evolution, clinical trial expansion, and a focus on personalized, cost-effective cancer therapies.

Recent Developments:

In October 2025, AstraZeneca and Daiichi Sankyo announced that Datroway, a precision drug, improved survival rates in patients with advanced breast cancer in a late-stage trial. This development paves the way for more widespread approvals and possible market expansion.

In June 2025, Bristol Myers Squibb signed a $11 billion strategic collaboration agreement with BioNTech. The collaboration entails the co-development and commercialization of BioNTech's investigational bispecific antibody, BNT327, which targets a variety of solid tumor types. BioNTech received an initial payment of $1.5 billion, with non-contingent anniversary payments through 2028 and potential milestone payments of up to $7.6 billion. This collaboration represents a significant investment in the advancement of novel immuno-oncology therapies in the global anticancer drug market, intending to accelerate the development of this bispecific antibody in multiple indications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis
  • Pfizer
  • Merck & Co. (MSD)
  • Bristol Myers Squibb (BMS)
  • AstraZeneca
  • Roche/Genentech
  • Johnson & Johnson/Janssen
  • Sanofi
  • Eli Lilly & Co.
  • Takeda
  • Amgen
  • BeiGene
  • Regeneron
  • Bluebird Bio
  • Seagen
  • Moderna
  • Genmab
  • Incyte
  • Exelixis
  • Hutchmed / Chi-Med
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Subcutaneous
  • Oral
  • Topical / Localized

GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
  • Monoclonal Antibodies / Biologics
  • Hormone Therapy
  • Targeted Therapy
  • Others (Oncolytic viruses, combination therapies, adjuncts)

GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Gynaecologic Cancer
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Solid (Tablets, Capsule)
  • Injectable (Prefilled Syringes, Others)
  • Liquid
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Anticancer Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Anticancer Drug Market Snippet by Route of Administration
    • 2.1.2. Anticancer Drug Market Snippet by Drug Class
    • 2.1.3. Anticancer Drug Market Snippet by Indication
    • 2.1.4. Anticancer Drug Market Snippet by Distribution Channels
    • 2.1.5. Anticancer Drug Market Snippet by Dosage Form
    • 2.1.6. Anticancer Drug Market Snippet by End-Users
    • 2.1.7. Anticancer Drug Market Snippet by Country
    • 2.1.8. Anticancer Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Anticancer Drug Key Market Trends

  • 3.1. Anticancer Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Anticancer Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Anticancer Drug Market Opportunities
  • 3.4. Anticancer Drug Market Future Trends

4. Anticancer Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Anticancer Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Anticancer Drug Market Landscape

  • 6.1. Anticancer Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Anticancer Drug Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Intravenous (IV)
    • 7.1.3. Subcutaneous
    • 7.1.4. Oral
    • 7.1.5. Topical / Localized

8. Anticancer Drug Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
    • 8.1.4. Monoclonal Antibodies / Biologics
    • 8.1.5. Hormone Therapy
    • 8.1.6. Targeted Therapy
    • 8.1.7. Others (Oncolytic viruses, combination therapies, adjuncts)

9. Anticancer Drug Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Breast Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Gastrointestinal Cancer
    • 9.1.6. Blood Cancer
    • 9.1.7. Gynaecologic Cancer
    • 9.1.8. Others

10. Anticancer Drug Market - By Distribution Channels

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channels, 2024 & 2032 (%)
    • 10.1.2. Online Pharmacy
    • 10.1.3. Hospital Pharmacy
    • 10.1.4. Retail Pharmacy

11. Anticancer Drug Market - By Dosage Form

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 11.1.2. Solid (Tablets, Capsule)
    • 11.1.3. Injectable (Prefilled Syringes, Others)
    • 11.1.4. Liquid
    • 11.1.5. Others

12. Anticancer Drug Market - By End-Users

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 12.1.2. Specialty Clinics
    • 12.1.3. Hospitals
    • 12.1.4. Homecare
    • 12.1.5. Others

13. Anticancer Drug Market- By Geography

  • 13.1. Introduction
    • 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 13.2. North America
    • 13.2.1. Overview
    • 13.2.2. Anticancer Drug Key Manufacturers in North America
    • 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.2.7. North America Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.2.8. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.2.9. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.2.10. U.S.
      • 13.2.10.1. Overview
      • 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.10.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.2.10.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.2.10.6. U.S. Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.2.10.7. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.2.10.8. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.2.11. Canada
      • 13.2.11.1. Overview
      • 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.11.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.2.11.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.2.11.6. Canada Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.2.11.7. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.2.11.8. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.3. Europe
    • 13.3.1. Overview
    • 13.3.2. Anticancer Drug Key Manufacturers in Europe
    • 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.3.7. Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.3.8. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.3.9. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.10. Germany
      • 13.3.10.1. Overview
      • 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.10.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.10.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.10.6. Germany Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.10.7. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.10.8. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.11. UK
      • 13.3.11.1. Overview
      • 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.11.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.11.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.11.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.11.6. UK Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.11.7. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.11.8. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.12. France
      • 13.3.12.1. Overview
      • 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.12.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.12.6. France Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.12.7. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.12.8. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.13. Italy
      • 13.3.13.1. Overview
      • 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.13.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.13.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.13.6. Italy Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.13.7. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.13.8. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.14. Spain
      • 13.3.14.1. Overview
      • 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.14.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.14.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.14.6. Spain Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.14.7. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.14.8. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.15. The Netherlands
      • 13.3.15.1. Overview
      • 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.15.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.15.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.15.6. The Netherlands Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.15.7. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.15.8. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.16. Sweden
      • 13.3.16.1. Overview
      • 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.16.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.16.6. Sweden Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.16.7. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.16.8. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.17. Russia
      • 13.3.17.1. Overview
      • 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.17.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.17.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.17.6. Russia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.17.7. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.17.8. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.18. Poland
      • 13.3.18.1. Overview
      • 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.18.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.18.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.18.6. Poland Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.18.7. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.18.8. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.19. Rest of Europe
      • 13.3.19.1. Overview
      • 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.19.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.19.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.19.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.19.6. Rest of the Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.19.7. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.19.8. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.4. Asia Pacific (APAC)
    • 13.4.1. Overview
    • 13.4.2. Anticancer Drug Key Manufacturers in Asia Pacific
    • 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.4.7. APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.4.8. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.4.9. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.10. China
      • 13.4.10.1. Overview
      • 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.10.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.10.6. China Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.10.7. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.10.8. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.11. India
      • 13.4.11.1. Overview
      • 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.11.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.11.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.11.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.11.6. India Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.11.7. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.11.8. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.12. Japan
      • 13.4.12.1. Overview
      • 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.12.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.12.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.12.6. Japan Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.12.7. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.12.8. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.13. South Korea
      • 13.4.13.1. Overview
      • 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.13.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.13.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.13.6. South Korea Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.13.7. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.13.8. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.14. Australia
      • 13.4.14.1. Overview
      • 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.14.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.14.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.14.6. Australia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.14.7. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.14.8. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.15. Indonesia
      • 13.4.15.1. Overview
      • 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.15.6. Indonesia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.15.7. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.15.8. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.16. Thailand
      • 13.4.16.1. Overview
      • 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.16.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.16.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.16.6. Thailand Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.16.7. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.16.8. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.17. Philippines
      • 13.4.17.1. Overview
      • 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.17.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.17.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.17.6. Philippines Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.17.7. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.17.8. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.18. Rest of APAC
      • 13.4.18.1. Overview
      • 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.18.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.18.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.18.7. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.18.8. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.5. Latin America (LATAM)
    • 13.5.1. Overview
    • 13.5.2. Anticancer Drug Key Manufacturers in Latin America
    • 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.5.7. LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.5.8. LATAM Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.5.9. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.10. Brazil
      • 13.5.10.1. Overview
      • 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.10.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.10.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.10.6. Brazil Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.10.7. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.10.8. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.11. Mexico
      • 13.5.11.1. Overview
      • 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.11.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.11.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.11.6. Mexico Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.11.7. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.11.8. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.12. Argentina
      • 13.5.12.1. Overview
      • 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.12.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.12.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.12.6. Argentina Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.12.7. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.12.8. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.13. Colombia
      • 13.5.13.1. Overview
      • 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.13.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.13.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.13.6. Colombia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.13.7. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.13.8. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.14. Rest of LATAM
      • 13.5.14.1. Overview
      • 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.14.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.14.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.14.6. Rest of LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.14.7. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.14.8. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.6. Middle East and Africa
    • 13.6.1. Overview
    • 13.6.2. Anticancer Drug Key Manufacturers in Middle East and Africa
    • 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.6.8. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.6.9. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.10. Saudi Arabia
      • 13.6.10.1. Overview
      • 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.10.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.10.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.10.6. Saudi Arabia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.10.7. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.10.8. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.11. United Arab Emirates
      • 13.6.11.1. Overview
      • 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.11.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.11.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.11.6. United Arab Emirates Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.11.7. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.11.8. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.12. Israel
      • 13.6.12.1. Overview
      • 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.12.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.12.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.12.6. Israel Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.12.7. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.12.8. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.13. Turkey
      • 13.6.13.1. Overview
      • 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.13.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.13.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.13.6. Turkey Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.13.7. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.13.8. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.14. Algeria
      • 13.6.14.1. Overview
      • 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.14.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.14.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.14.6. Algeria Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.14.7. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.14.8. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.15. Egypt
      • 13.6.15.1. Overview
      • 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.15.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.15.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.15.6. Egypt Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.15.7. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.15.8. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.16. Rest of MEA
      • 13.6.16.1. Overview
      • 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.16.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.16.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.16.7. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.16.8. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Anticancer Drug Industry

  • 14.1. Competitive Benchmarking
    • 14.1.1. Competitive Dashboard
    • 14.1.2. Competitive Positioning
  • 14.2. Company Profiles
    • 14.2.1. Novartis
    • 14.2.2. Pfizer
    • 14.2.3. Merck & Co. (MSD)
    • 14.2.4. Bristol Myers Squibb (BMS)
    • 14.2.5. AstraZeneca
    • 14.2.6. Roche/Genentech
    • 14.2.7. Johnson & Johnson/Janssen
    • 14.2.8. Sanofi
    • 14.2.9. Eli Lilly & Co.
    • 14.2.10. Takeda
    • 14.2.11. Amgen
    • 14.2.12. BeiGene
    • 14.2.13. Regeneron
    • 14.2.14. Bluebird Bio
    • 14.2.15. Seagen
    • 14.2.16. Moderna
    • 14.2.17. Genmab
    • 14.2.18. Incyte
    • 14.2.19. Exelixis
    • 14.2.20. Hutchmed / Chi-Med
    • 14.2.21. Others

15. 360 Degree Analyst View

16. Appendix

  • 16.1. Research Methodology
  • 16.2. References
  • 16.3. Abbreviations
  • 16.4. Disclaimer
  • 16.5. Contact Us